Clinically Significant Drug Interactions with Cyclosporin: An Update

Clinical Pharmacokinetics

Volumn 30, Issue 2, 1996, Pages 141-179

  Campana, Carlo ^a   Regazzi, Mario B ^a   Buggia, Isabella ^a   Molinaro, Mariadelfina ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AMINOGLYCOSIDE; AMIODARONE; AMPHOTERICIN B; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBOCYTIC AGENT; ANTIVIRUS AGENT; CALCIUM CHANNEL BLOCKING AGENT; COLCHICINE; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLAVONOID; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MELPHALAN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SEX HORMONE; TACROLIMUS; UNINDEXED DRUG;

AUTOIMMUNITY; BONE MARROW TRANSPLANTATION; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG METABOLISM; DRUG MONITORING; DRUG THERAPY; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIVER TOXICITY; LIVER TRANSPLANTATION; MORBIDITY; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; ORAL DRUG ADMINISTRATION; PANCREAS TRANSPLANTATION; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW;

ABSORPTION; ADMINISTRATION, ORAL; CYCLOSPORINE; DOSAGE FORMS; DRUG INTERACTIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; KIDNEY; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 0030042485     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630020-00004     Document Type: Article

References (367)

1. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6: 468-75
2. Kahan BD, Grevel J. Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. Transplantation 1988; 43: 631-44
3. Kennedy MS, Yee GC, McGuire TR, et al. Correlation of serum cyclosporine concentration with renal dysfunction in marrow transplant recipients. Transplantation 1985; 40: 249-53
4. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, et al. Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet 1986; 11: 107-32
5. Rodighiero V. Therapeutic drug monitoring of cyclosporin: practical applications and limitations. Clin Pharmacokinet 1989; 16: 27-37
6. Yee GC, Kennedy MS. Cyclosporine. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principle of therapeutic drug monitoring. Washington, DC: Applied Therapeutics, 1986
7. Yee GC, McGuire TR. Pharmacokinelic drug interactions with cyclosporin (part 1). Clin Pharmacokinet 1990; 19: 319-32
8. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin (part 2). Clin Pharmacokinet 1990; 19: 400-15
9. Klintmalm GBC, Iwatsuki I, Starzl TE. Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet 1981; i: 470-1
10. Puschett JB, Greenberg A, Holley J, et al. The spectrum of cyclosporine nephrotoxicity. Am J Nephrol 1990; 10 (4): 296-309
11. McCauley J, Van Thiel DH, Starzl TE, et al. Acute and chronic renal failure in liver transplantation. Nephron 1990; 55: 121-8
12. Atkinson K, Biggs J, Darveniza P, et al. Cyclosporine-associated central nervous system toxicity after allogeneic bone marrow transplantation. Transplantation 1984; 38: 34-7
13. DeGroen PC, Aksamit AJ, Rakela J, et al. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. New Engl J Med 1987; 317 (14): 861-6
14. Grant D, Wall W, Duff J, et al. Adverse effect of cyclosporine therapy following liver transplantation. Transplant Proc 1987; 19 (4): 3463-5
15. Kahan BD. Cyclosporine. New Engl J Med 1989; 321: 1725-38
16. Wood AJ, Maurer G, Niederberger W, et al. Cyclosporine: pharmacokinetics, metabolism and drug interactions. Transplant Proc 1983; 15 Suppl. 1: 2409-12
17. Lindholm A. Factors influencing the pharmacokinetics of cyclosporine in man. Ther Drug Monit 1991; 13: 465-77
18. Drewe J, Beglinger C, Kissel T. The absorption site of cyclosporin in the human gastrointestinal tract. Br J Clin Pharmacol 1992; 33 (1): 39-43
19. Kahan BD, Ried M, Newburger J. Pharmacokinetics of cyclosporine in human renal transplantation. Transplant Proc 1983; 15: 446-53
20. Ptachcinski RJ, Venkataramanan R, Rosenthal JT, et al. Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther 1985; 38 (3): 296-300
21. Burckart GJ, Venkataramanan R, Ptachcinski RJ, et al. Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol 1986; 26: 647-51
22. Kahan BD, Kramer WG, Wideman C, et al. Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 1986; 41: 459-64
23. Andrews W, Iwatsuki S, Shaw BW, et al. Cyclosporine monitoring in liver transplant patients [letter]. Transplantation 1985; 39: 338
24. Venkataramanan R, Burckart GJ, Ptachcinski RJ. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis 1985; 5: 357-68
25. Mehta MU, Venkataramanan R, Burckart GJ, et al. Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 1988; 25: 579-84
26. Burckart GJ, Venkataramanan R, Ptachcinski RJ, et al. Cyclosporine pharmacokinetic profiles in liver, heart and kidney transplant patients as determined by high-performance liquid chromatography. Transplant Proc 1986; 18 (6 Suppl. 5): 129-36
27. Kahan BD, Dunn J, Fitts C, et al. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients. Transplant Proc 1994; 26 (5): 2940-2
28. Atkinson K, Biggs JC, Britton K, et al. Oral administration of cyclosporin A for recipients of allogeneic marrow transplants: implications of clinical gut dysfunction. Br J Haematol 1984; 56: 223-31
29. Burckart G, Starzl T, Williams L, et al. Cyclosporin monitoring and pharmacokinetics in pediatric liver transplant patients. Transplant Proc 1985; 17: 1172-5
30. Kovarik JM, Mueller EA, van Bree JB, et al. Reduced inter- and intraindividual variability in cyclosporine pharmacokinetics from a microemulsion formulation. J Pharm Sci 1994; 83: 444-6
31. Trull AK, Tan KKC, Uttridge J, et al. Cyclosporine absorption from microemulsion formulation in liver transplant recipients. Lancet 1993; 341: 433
32. Levy G, Grant D. Potential for CsA-Neoral in organ transplantation. Transplant Proc 1994; 26 (5): 2932-4
33. Wadhwa NK, Schroeder TJ, O'Flaherty E, et al. The effect of oral metoclopramide on the absorption of cyclosporine. Transplant Proc 1987; 19 (1 Pt 2): 1730-3
34. Finet L, Westeel PF, Hary L, et al. Effects of cisapride on the intestinal absorption of cyclosporine in renal transplant patients [abstract]. Gastroenterology 1991; 100: A209
35. Gupta SK, Bakran A, Johnson RWG, et al. Erythromycin enhances the absorption of cyclosporin. Br J Clin Pharmacol 1988; 25: 401-2
36. Rowland M, Gupta SK. Cyclosporin-phenytoin interaction: reevaluation using metabolite data. Br J Clin Pharmacol 1987; 24: 329-34
37. Freeman DJ, Laupacis A, Keown PA, et al. Evaluation of cyclosporin-phenytoin interaction with observations on cyclosporine metabolites. Br J Clin Pharmacol 1984; 18: 887-93
38. Riegelman S, Rowland M, Epstein WL. Griseofulvin-phenobarbital interaction in man. JAMA 1970; 213: 426-31
39. Putcha L, Nandiwada P, Feldman S, et al. Effect of heptabarbital on bioavailability of bishydroxycoumarin in the rat. Res Commun Chem Pathol Pharmacol 1978; 19: 67-74
40. Crow JW, Gibaldi M, Levy G. Comparative pharmacokinetics of coumarin anticoagulants, XLII: effect of phenobarbital on systemic availability of orally administered dicumarol in rats with ligated bile ducts. J Pharm Sci 1979; 68: 1309-12
41. Landgraf F, Landgraf-Leurs MMC, Nusser J, et al. Effect of somatostatine analogue (SMS201-995) on cyclosporine levels. Transplantation 1987; 44: 724-5
42. Rosenberg L, Dafoe DC, Schwartz R. Administration of somatostatin analog in the treatment of a fistula occurring after pancreas transplantation. Transplantation 1987; 43: 764-6
43. Santa T, Nishihara K, Horie S, et al. Decreased cyclosporine absorption after treatment with GoLytely lavage solution in a kidney transplant patient. Ann Pharmacother 1994; 28 (7-8): 963-4
44. Reichenspurner H, Meiser BM, Muschiol F, et al. Changes of resorption and metabolism of cyclosporine after heart transplantation by the influence of gastrointestinal agents. Transplant Proc 1994; 26 (5): 2800-1
45. Babany G, Morris RE, Babany I, et al. Evaluation of the in vivo dose-response relationship of immunosuppressive drugs using a mouse heart transplant model: application to cyclosporine. J Pharmacol Exp Ther 1988; 244: 259-62
46. Ried M, Gibbons S, Kwok D, et al. Cyclosporine levels in human tissues of patients treated for one week to one year. Transplant Proc 1983; 15 Suppl. 1/2: 2434-7
47. Lensmeyer GL, Wiebe DA, Carlson IH, et al. Concentration of cyclosporin A and its metabolite in human tissues postmortem. J Anal Toxicol 1991; 15: 110-5
48. Lemaire M, Tillement JP. Role of lipoproteins and erythrocytes in the in vitro binding and distribution of cyclosporin A in the blood. J Pharm Pharmacol 1982; 34: 715-8
49. Atkinson K, Britton K, Biggs J. Distribution and concentration of cyclosporin in human blood. J Clin Pathol 1984; 37: 1167-71
50. Mraz W, Kemkes BM, Knedel M. The role of lipoproteins in exchange and transfer of cyclosporine-results from in vitro investigations. Transplant Proc 1986; 18: 1281-4
51. Niederberger W, Lemaire M, Maurer G, et al. Distribution and binding of cyclosporine in blood and tissues. Transplant Proc 1983; 15 (4 Suppl. 1/2): 2419-21
52. Mraz W, Zink RA, Graf A, et al. Distribution and transfer of cyclosporine among the various human lipoprotein classes. Transplant Proc 1983; 15 Suppl. 1/2: 2426-9
53. Sgoutas D, MacMahon W, Love A, et al. Interaction of cyclosporin A with human lipoproteins. J Pharm Pharmacol 1986; 38: 583-8
54. De Groen PC. Cyclosporine, low density lipoprotein and cholesterol. Majo Clin Proc 1988; 63: 1012-21
55. Superko HR, Haskell WL, Di-Ricco CD. Lipoprotein and hepatic lipase activity and high-density lipoprotein subclasses after cardiac transplantation. Am J Cardiol 1990; 66: 1131-4
56. Harris KPG, Russel GI, Parvin SD, et al. Alterations in lipid and carbohydrate metabolism attributable to cyclosporin A in renal transplant recipients. BMJ 1986; 292: 16
57. McEvoy GK, editor. American Hospital Formulary Service (AHFS) Drug Information 92. Bethesda (MD): American Society of Hospital Pharmacists, 1992; 964
58. Sundararajan V, Cooper DKC, Muchmore J, et al. Interaction of cyclosporine and probucol in heart transplant patients. Transplant Proc 1991; 23: 2028-32
59. Gallego C, Sanchez P, Planells C, et al. Interaction between prebucol and cyclosporine in renal transplant patients. Ann Pharmacother 1994; 28 (7-8): 940-3
60. Blum CB, Levy RI. Current therapy for hypercholesterolaemia. JAMA 1989; 261: 3582-7
61. Anderson JL, Schroeder JS. Effect of probucol on hyperlipidemic patients with cardiac allograft. J Cardiovasc Pharmacol 1979; 1: 353-65
62. Tobert JA. Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. New Engl J Med 1988; 318: 47-8
63. Keogh A, Day R, Critchley L, et al. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc 1988; 20: 27-30
64. Bertault-Peres P, Bonfils C, Fabre G, et al. Metabolism of cyclosporin A. Implication of the macrolide antibiotic inducible cytochrome P-450 3c from rabbit liver microsomes. Drug Metab Dispos 1987; 15 (3): 391-8
65. Fabre I, Fabre G, Maurel P, et al. Metabolism of cyclosporine A. III: Interaction of the macrolide antibiotic erythromycin, using rabbit hepatocytes and microsome fractions. Drug Metab Dispos 1988; 16: 296-301
66. Aoyama T, Yamano S, Waxman DJ, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450IIIA gene product that is differentially expressed in adult human liver. CDNA and deduced amino acid sequence and distinct specificity on cDNA-expressed hPCN1 and hPCN3 for metabolism of steroid hormones and cyclosporine. J Biol Chem 1989; 264 (18): 10388-95
67. Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporinc A. IV: Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporine A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17(2): 197-207
68. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43 (6): 630-5
69. Nebert DW, Nelson DR, Adesnik M, et al. The P-450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 1989; 8: 1-13
70. Fahr A. Cyclosporin clinical pharmacokinetics. Clin Pharmacokinet 1993; 24 (6): 472-95
71. Copeland KR, Thliveris JA, Yatscoff RW. Toxicity of cyclosporine metabolites. Ther Drug Monit 1990; 12: 525-32
72. Lokiec F, Poirer O, Gluckman E, et al. Pharmacokinetic study of cyclosporine A. In: Touraine J, Gluckman E, Griscelli G, editors. Bone marrow transplantation in Europe. II. Amsterdam: Excerpta Medica, 1981: 160-4
73. Ferguson RM, Sutherland DER, Simmons RL, et al. Ketoconazo e, cyclosporin metabolism, and renal transplantation [letter]. Lancet 1982; ii: 882-3
74. Daneshmend TK. Ketoconazole-cyclosporine intercation [letter]. Lancet 1982; ii: 1342-3
75. Dieperink H, Kemp E, Leyssac PP, et al. Ketoconzole and cyclosporin A: combined effects on rat renal function and on serum and tissue cyclosporin A concentration. Clin Nephrol 1986; 25 Suppl. 1: S137-43
76. Morgenstern GR, Powles R, Robinson B, et al. Cyclosporin interaction with ketoconazole and melphalan [letter]. Lancet 1982; ii: 1342
77. Smith J, Hows J, Donnelly P, et al. Interaction of cyclosporine A and ketoconazole. Exp Hematol 11 1983; Suppl. 13: 176-8
78. White DJ, Blatchford NR, Cauwenbergh G. Cyclosporine and ketoconazole. Transplantation 1984; 37: 214-5
79. Gumbleton M, Brown JE, Hawksworth G, et al. The possible relationship between hepatic drug metabolism and ketoconazole enhancement of cyclosporine nephrotoxicity. Transplantation 1985; 40 (4): 454-5
80. Shepard JH, Canafax DM, Simmons RL, et al. Cyclosporine-ketoconazole: a potentially dangerous drug-drug intercation [letter]. Clin Pharm 1986; 5: 468
81. Ryffel B, Muller AM, Mihatsch MJ. Experimental cyclosporine nephrotoxicity: risks of concomitant chemotherapy. Clin Nephrol 1986; 25 Suppl. 1: S121-5
82. Schroeder TJ, Melvin DB, Clardy CW, et al. Use of cyclosporine and ketoconazole without nephrotoxicity in two heart transplant recipients. J Heart Transplant 1987; 6: 84-9
83. Charles BG, Ravenscroft PJ, Rigby RJ. The ketoconazole-cyclosporine interaction in an elderly renal transplant patient. Aust NZ J Med 1989; 19: 292-3
84. Veraldi S, Menni S. Severe gingival hyperplasia following cyclosporin and ketoconazole therapy [letter]. Intern J Dermatol 1988; 27: 730
85. Girardet RE, Melo JC, Fox MS, et al. Concomitant administration of cyclosporine and ketoconazole for three and a half years in one heart transplant recipient. Transplantation 1989; 48: 887-90
86. Kiss D, Thiel G. Glucose-intolerance and prolonged renaltransplant insufficiency due to ketoconazole-cyclosporin A interaction [letter]. Clin Nephrol 1990; 33: 207-8
87. First MR, Schroeder TJ, Weiskittel P, et al. Concomitant administration of cyclosporin and ketoconazole in renal transplant recipients. Lancet 1989; ii: 1198-201
88. First MR, Schroeder TJ, Alexander JW, et al. Cyclosporine dose reduction by ketoconazole administration in renal transplant recipients. Transplantation 1991; 51: 365-70
89. Dieperink H, MØller J. Ketoconazole and cyclosporin [letter]. Lancet 1982; ii: 1217
90. Sugar AM, Saunders C, Idelson BA, et al. Interaction of fluconazole and cyclosporine [letter]. Ann Intern Med 1989; 110: 884
91. Collignon P, Hurley B, Mitchell D. Interaction of fluconazole with cyclosporin. Lancet 1989: i: 1262
92. Canafax DM, Graves NM, Hilligoss DM, et al. Interaction between cyclosporine and fluconazole in renal allograft recipients. Transplantation 1991; 51 (5): 1014-8
93. Kwan JT, Foxall PJ, Davidson DG, et al. Interaction of cyclosporin and itraconazole. Lancet 1987; ii: 282
94. Trenk D, Brett W, Jahnchen E, et al. Time course of cyclosporin/itraconazole interaction. Lancet 1987; ii: 1335-6
95. Novakova I, Donnelly P, de Witte TD, et al. Itraconazole and cyclosporine nephrotoxicity. Lancet 1987; ii: 920-1
96. Horton CM, Freeman CD, Nolan PE, et al. Cyclosporine interactions with miconazole and other azole-antimycotics: a case report and review of the literature. J Heart Lung Transplant 1992; 11 (6): 1127-32
97. Butman SM, Wild JC, Nolan PE, et al. Prospective study of the safety and financial benefit of ketoconazole as adjunctive therapy to cyclosporine after heart transplantation. J Heart Lung transplant 1991; 10: 351-8
98. Gueco IP, Tan-Torres T, Baniga U, et al. Ketoconazole in posttransplant triple therapy: comparison of costs and outcomes. Transplant Proc 1992; 24 (5): 1709-14
99. Albengres E, Tillement JP. Cyclosporin and ketoconazole, drug interaction or therapeutic association? Int J Clin Pharmacol Ther Toxicol 1992; 30(12): 555-70
100. Gandhi BV, Kale S, Bhowmik DM, et al. Concomitant administration of cyclosporine and ketoconazole in renal transplant patients. Transplant Proc 1992; 24 (5): 1715
101. First MR, Schroeder TJ, Michael A, et al. Cyclosporine-keloconazole interaction. Long term follow up and preliminary results of a randomized trial. Transplantation 1993; 55 (5): 1000-4
102. Patton PR, Brunson ME, Pfaff WW, et al. Preliminary report of diltiazem and ketoconazole. Transplantation 1994; 57: 889-92
103. Back DJ, Tjia JF. Comparative effects of the antimycotic drugs, ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporine by human liver microsomes. Br J Clin Pharmacol 1991; 32: 624-6
104. Grant SM, Clissold SP. Itraconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989; 37: 310-44
105. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-916
106. Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113: 327-9
107. Zylber-Katz E. Multiple drug interactions with cyclosporine in a heart transplant patient. Ann Pharmacother 1995; 9: 127-31
108. Ptachcinski RJ, Carpenter BJ, Burckart G, et al. Effect oferythromycin on cyclosporine levels. New Engl J Med 1985; 313 (22): 1416-7
109. Hourmant M, Le Bigot JF, Vernillet L, et al. Coadministration of erythromycin results in an increase of blood cyclosporine to toxic levels. Transplant Proc 1985; 17 (6): 2723-7
110. Gonwa TA, Nghiem DM, Schulak JA, et al. Erythromycin and cyclosporine. Transplantation 1986; 41: 797-9
111. Jensen CWB, Flechner SM, Van Buren CT, et al. Exacerbation of cyclosporine toxicity by concomitant administration of erythromycin. Transplantation 1987; 43: 263-70
112. Murray BM, Edwards L, Morse GD, et al. Clinically important interaction of cyclosporine and erythromycin. Transplantation 1987; 43: 602-4
113. Lysz K, Rosemberg JC, Kaplan MP, et al. Interaction of erythromycin with cyclosporine. Transplant Proc 1988; 20: 543-8
114. Grino JM, Sabate J, Castelao AM, et al. Erythromycin and cyclosporine (letter). Ann Intern Med 1986; 105: 467-8
115. Wadhwa NK, Schroeder TJ, O'Flaherty E, et al. Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient. Ther Drug Monit 1987; 9: 123-5
116. Martell R, Heinrichs D, Stiller CR, et al. The effect of erythromycin in patients treated with cyclosporine. Ann Intern Med 1986; 104: 660-1
117. Kohan DE. Possible interaction between cyclosporine and erythromycin [letter]. New Engl J Med 1986; 314: 448
118. Kessler M, Louis J, Renoult E, et al. Interaction between cyclosporin and erythromycin in a kidney transplant patient. Eur J Clin Pharmacol 1986; 30: 633-4
119. Ben-Ari J, Eisenstein B, Davidovits M, et al. Effect of erythromycin on blood cyclosporine concentrations in kidney transplant patients. J Pediatr 1988; 112: 992-3
120. Harnett JD, Parfrey PS, Paul MD, et al. Erythromycincyclosporine interaction in renal transplant recipients. Transplantation 1987; 43: 316-8
121. Aoki FY, Yatscoff R, Jeffery J, et al. Effects of erythromycin on cyclosporine A kinetics in renal transplant patients [abstract]. Clin Pharmacol Ther 1987; 41: 221 (Abstract PIIID-4)
122. Freeman DJ, Martell R, Carruthers SG, et al. Cyclosporinerythromycin interaction in normal subjects. Br J Clin Pharmacol 1987; 23: 776-8
123. Danan G, Descatoire V, Pessayre D. Self-induction by erythromycin of its own transformation into a metabolic forming an inactive complex with reduced cytochrome P-450. J Pharmacol Exp Ther 1981; 218: 509-14
124. Larrey D, Funck-Brentano C, Breil P, et al. Effects of erythromycin on hepatic drug-metabolizing enzymes in humans. Biochem Pharmacol 1983; 32: 1063-8
125. Henriccson S, Lindholm A. Inhibition of cyclosporine metabolism by other drugs in vitro. Transplant Proc 1988; 20 Suppl. 2: 569-71
126. Wahlstrom E, Zamora JU, Teichman S. Improvement in cyclosporine-associated gingival hyperplasia with azithromycin therapy. New Engl J Med 1995; 332: 753-4
127. Gersema LM, Porter CB, Russel EH. Suspected drug interaction between cyclosporine and clarithromycin. J Heart Lung Transplant 1994; 13 (2): 343-5
128. Ferrari SL, Goffin E, Mourad M, et al. The interaction between clarithromycin and cyctosporine in kidney transplant recipients. Transplantation 1994; 58: 725-7
129. Krefl-Jais C, Billaud EM, Gaudry C, et al. Effect of josamycin on plasma cyclosporine levels. Eur J Clin Pharmacol 1987; 32: 327-8
130. Azanza J, Catalan M, Alvarez P, et al. Possible interactions between cyclosporine and josamycin. J Heart Transplant 1990; 9: 265-6
131. Couet W, Istin B, Seniuta P, et al. Effect of ponsinomycin on cyclosporin pharmacokinetics. Eur J Clin Pharmacol 1990; 39: 165-7
132. Herbrecht R, Liu KL, Bergerat JP. Interaction of cyclosporine with antimicrobial agents [letter]. Rev Infect Dis 1990; 12: 371
133. Billaud EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet 1990; 19: 499-502
134. Pessayre D, Larrey D, Vitaux J, et al. Formation of an inactive cytochrome P-450 Fe(II)-metabolite complex after administration of troleanomycin in humans. Biochem Pharmacol 1982; 31: 1699-704
135. Chan GL, Sinnott JT, Emmanuel PJ, et al. Drug interaction with cyclosporin: focus on antimicrobial agents. Clin Transplant 1992; 6: 141-53
136. Burke MD, MacIntyre F, Cameron D, et al. Cyclosporine A metabolism and drug interactions. In: Thomson AW, Sandimmun®: mode of action and clinical applications. Dondrech, The Netherlands: Kluwer Academic, 1989; 267
137. Tinel M, Descatoire V, Larrey D, et al. Effects of clarithromycin on cytochrome P-450: comparison with other macrolides. J Pharmacol Exp Ther 1989; 250: 746-51
138. Bolt HM, Kappus H, Bolt M. Effect of rifampicin treatment on the metabolism of oestradiol and 17-alpha-ethinyloestradiol by human liver microsomes. Eur J Clin Pharmacol 1975; 8: 301-7
139. Jezequel AM, Orlandi F, Tenconi LT. Changes of the smooth endoplasmic reticulum induced by rifampicin in human and guinea-pig hepatocytes. Gut 1971; 12: 984-7
140. Hopps V, Galione A, Biondi F, et al. Rifampicin reduces nephrotoxicity of cyclosporine A in rats: studies of renal enzyme excretion. Transplant Proc 1988; 20 Suppl. 2: 557-60
141. Cockburn ITR, Krupp P. An appraisal of drug interactions with Sandimmun. Transplant Proc 1989; 21: 3845-50
142. Muakkassah SE, Bidlock WR, Yang WC. Mechanism of the inhibitory action of isoniazid on microsomal drug metabolism. Biochem Pharmacol 1984; 30: 1651-8
143. Jarewicz WA, Gunson BK, Ismail T, et al. Cyclosporin and antituberculous therapy. Lancet 1985; i: 1342-3
144. Daniels NJ, Dover JS, Schachter RK. Interaction between cyclosporin and rifampicin. Lancet 1984; ii: 639
145. Allen RD, Hunnisett AG, Morris PJ. Cyclosporin and rifampicin in renal transplantation. Lancet 1985; i: 980
146. Van Euren D, Wideman CA, Ried M, et al. The antagonistic effect of rifampin upon cyclosporine bioavailability. Transplant Proc 1984; 16: 1642-5
147. Langhoff E, Madsen S. Rapid metabolism of cyclosporin and prednisone in kidney transplant patients receiving tuberculostatic treatment. Lancet 1983; ii: 1031
148. Modry DL, Stinson EB, Oyer PE, et al. Acute rejection and massive cyclosporine requirements in heart transplant recipients treated with rifampin. Transplantation 1985; 39: 313-4
149. Al-Su aiman MH, Dhar JM, AL-Khader AA. Successful use of rifampicin in the treatment of tubecolosis in renal transplant patients immunossuppressed with cyclosporine. Transplantation 1990; 50: 597-8
150. Renoult E, Hubert J, Trechot P, et al. Effect of topical rifamycin SV treatment on cyclosproin A blood levels in renal transplant recipient. Eur J Clin Pharmacol 1991; 40: 433-4
151. Arora SK. Correlation of structure and activity in ansamycins. Molecular structure of sodium rifamycin SV. Molec Pharmacol 1983; 23: 133-40
152. Bonazzi P, Novelli G, Galcazzi R. The interaction of rifamycin SV with the hepatic transport and sulfation of taurolithocolic acid in rats. Pharmacol Res Commun 1986; 18: 675-85
153. Vandevelde C, Chang A, Andrews D, et al. Rifampicin and ansamycin interactions with cyclosporine after renal transplantation. Pharmacotherapy 1987; 11 (1): 88-9
154. Veremis SA, Maddux MS, Pollak R, et al. Subtherapeutic cyclosporine concentrations during nafcillin therapy. Transplantation 1987; 43: 913-5
155. Zazgotnik J, Schein W, Heimberger K, et al. Potentiation of neurotoxic side effects by coadministration of imipenem to cyclosporine therapy in a kidney transplant recipients-synergism of side-effects or drug-interaction? Clin Nephrol 1986; 26: 265-6
156. Jahansouz FJ, Kriett JM, Smith CM, et al. Potentiation of cyclosporine nephrotoxicity by nafcillin in lung transplant recipients. Transplantation 1993; 55 (5): 1045-8
157. Lake KD. Management of drug interactions with cyclosporine. Pharmacotherupy 1991; 11 Suppl.: 110S-118S
158. Linton AL, Clark WF, Driedger AA, et al. Acute interstitial nephritis due to drugs: review of literature with a report of nine cases. Ann Inter Med 1980; 93: 735-41
159. Neilson EG. Pathogenesis and therapy of interstistial nephritis. Kidney Int 1989; 35: 1257-70
160. Mraz W, Sido B, Knedel M, et al. Concomitant immunosuppressive and antibiotic therapy-reduction of cyclospoine A blood levels due to treatment with imipenem/cilastatin. Transplant Proc 1987; 19: 4017-20
161. Sido B, Hammer C, Mraz W, et al. Nephroprotective effect of imipenem/cilastatin in reducing cyclosporine toxicity. Transplant Proc 1987; 19(1 Pt 2): 1755-8
162. Thompson JF, Chalmers DHK, Hunnisett AGW, et al. Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with cyclosporine. Transplantation 1983; 36: 204-6
163. Jones DK, Hakim M, Wallwork J, et al. Serious interaction between cyclosporine A and sulphadimidine. BMJ 1986; 292: 728-9
164. Wallwork J, McGregor CGA, Wells FC, et al. Cyclosporin and intravenous sulphadimidine and trimethoprim therapy [letter]. Lancet 1983; i: 366-7
165. Freeman DJ, Laupacis A, Keown P, et al. The effects of agents that alter drug metabolizing enzyme activity on the pharmacokinetics of cyclosporine [abstract]. Ann R Coll Phys Surg Can 1984; 17: 301
166. D'Souza MJ, Pollack SH, Solomon HM. Cyclosporine-phenytoin interaction. Drug Metab Dispos 1988; 16: 256-8
167. Park BK, Breckenridge AM. Clinical implications of enzyme induction and enzyme inhibition. Clin Pharmacokinet 1981; 6: 1-24
168. Keown PA, Stiller CR, Laupacis AL, et al. The effects and side effects of cyclosporine: relationship to drug pharmacokinetics. Transplant Proc 1982; 14: 659-61
169. Keown PA, Laupacis A, Carruthers G, et al. Interaction between phenytoin and cyclosporine following organ transplantation. Transplantation 1984; 38: 304-6
170. Hoyer PF, Offner G, Wonigeit K, et al. Dosage of cyclosporin A in children with renal transplants. Clin Nephrol 1984; 22: 68-71
171. Wideman CA. Pharmacokinetic monitoring of cyclosporine. Transplant Proc 1983; 15 Suppl. 1: 3168-75
172. Carstensen H, Jacobsen N, Dieperink H. Interaction between cyclosporin A and phenobarbitone [letter]. Br J Clin Pharmacol 1986; 21: 550-1
173. Burckart GJ, Venkataramanan R, Starzl T, et al. Cyclosporine clerance in children following organ transplantation [abstract]. J Clin Pharmacol 1984; 24: 412
174. Klintmalm G, Säwe J, Ringdén O, et al. Cyclosporine plasma levels in renal transplant patients. Association with renal toxicity and allograft rejection. Transplantation 1985; 39: 132-7
175. Lele P, Peterson P, Yang S, et al. Cyclosporine and tegretol: another drug interaction [abstract]. Kidney Int 1985; 27: 344
176. Hillebrand G, Castro LA, Van Scheidt W, et al. Valproate for epilepsy in renal transplant recipients receiving cyclosporine. Transplantation 1987; 43: 915-6
177. Fischman MA, Hull D, Bartus SA, et al. Valproate for epilepsy in renal transplant recipients receiving cyclosporine. Transplantation 1989; 48: 542
178. Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: a review. Gut 1984; 25: 673-81
179. Dreifuss FE, Santilli N, Langer DH, et al. Valproic acid hepatic fatalities: a retrospective review. Neurology 1977; 37: 379-85
180. Zimmerman HJ, Ishak KG. Valproate-induced hepatic injury: analyses of 23 fatal cases. Hepatology 1982; 2: 591-7
181. MacDonald P, Hackworthy R, Keogh A, et al. Atrial overdrive pacing for reversion of atrial flutter after cardiac transplantation [abstract]. J Heart Transplant 1990; 9: 68
182. Mamprin F, Mullins P, Graham T, et al. Amiodarone-cyclosporine interaction in cardiac transplantation [letter]. Am Heart J 1992; 123: 1725-6
183. Nicolau DP, Uber WE, Crumbley AJ III, et al. Amiodarone-cyclosporine interaction in a heart transplant patient. J Heart Lung Transplant 1992; 11 (31): 564-8
184. Chitwood KK, Abdul-Haqq AJ, Heim-Duthoy KL. Cyclosporine-amiodarone interaction. Ann Pharmacother 1993; 27: 569-71
185. Flower RJ, Moncada S, Vane JR. Analgesic: antipyretics and antiinflammatory agents: drugs employed in the treatment of gout. In: Gilman AG, Goodman LS, Gilman A, editors. The pharmacological basis of therapeutics. 6th ed. New York: Macmillan, 1980: 682-723
186. Stevens SL, Goldman MH. Cyclosporine toxicity associated with allopurinol. South Med J 1992; 85 (12): 1265-6
187. Gorrie M, Beaman M, Nicholls A, et al. Allopurinol interaction with cyclosporin. BMJ 1994; 308: 113
188. Dawidson I, Rooth P, Fry WR, et al. Prevention of acute cyclosporine-induced renal blood flow inhibition and improved immunosuppression with verapamil. Transplantation 1989; 48: 575-9
189. Corteza Q, Shen R, Revie D, et al. Effects of calcium channel blockers on in vivo cellular immunity in mice. Transplantation 1989; 47: 339-42
190. Weir MR, Peppler R, Gomolka D, et al. Additive inhibitory effect on cyclosporine and verapamil may occur through different mechanisms that may be dependent or independent of the slow calcium channel. Transplant Proc 1989; 21: 866-70
191. Colombani PM, Bright EC, Wells M, et al. Drug-drug interaction between cyclosporine and agents affecting calcium-dependent lymphocyte proliferation. Transplant Proc 1989; 21: 840-1
192. Dawidson I, Rooth P, Fisher D, et al. Verapamil ameliorates acute cyclosporine A (CsA) nephroloxicity and improves immunosuppression after cadaver renal transplantation. Transplant Proc 1989; 21: 1511-3
193. Kirk AJB, Omar I, Bateman DN, et al. Cyclosporine-associated hypertension in cardiopulmonary transplantation. The beneficial effect of nifedipine on renal function. Transplantation 1989; 48: 428-30
194. Gardner P. Calcium and T lymphocyte activation. Cell 1989; 59: 15-20
195. Birx DL, Berger M, Fleisher TA. The interference of T-cell activation by calcium channel blocking agents. J Immunol 1984; 133: 2904-9
196. McMillen MA, Lewis T, Jaffee BM, et al. Verapamil inhibition of lymphocyte proliferation and function in vitro. J Surg Res 1985; 39: 76-80
197. Wagner K, Henkel M, Heinemeyer G, et al. Interactions of calcium blockers and cyclosporine. Transplant Proc 1988; 20 Suppl. 2: 561-8
198. Lindholm A, Henricsson S. Verapamil inhibits cyclosporin metabolism [letter]. Lancet 1987; i: 1262-3
199. Maggio TG, Bartels DW. Increased cyclosporine blood concentrations due to verapamil interaction. Drug Intell Clin Pharm 1988; 22: 705-7
200. Robson RA, Fraenkel M, Barrait LJ, et al. Cyclosporine-verapamil interaction. Br J Clin Pharmacol 1988; 25: 402-3
201. Sabatè I, Griño J, Castelao AM, et al. Evaluation of cyclosporine-verapamil interaction, with observations on parent cyclosporin and metabolites. Clin Chem 1988; 34: 2151-2
202. Cantarovich M, Hiesse C, Lockiec F, et al. Confirmation of the interaction between cyclosporine and the calcium channel blocker nicardipine in renal transplant patients. Clin Nephrol 1987; 28: 190-3
203. Kessler M, Netter P, Renoult E, et al. Influence of nicardipine on renal function and plasma cyclosporin in renal transplant patients. Eur J Clin
204. Deray G, Aupetit B, Martinez F, et al. Cyclosporin-nicardipine interaction [letter]. Am J Nephrol 1989; 9: 349
205. Sabatè I, Griño JM, Castelao AM, et al. Cyclosporin-diltiazem interaction: comparison of cyclosporin levels measured with two monoclonal antibodies. Transplant Proc 1989; 21: 1460-1
206. Griño JM, Sabatè I, Castelao AM, et al. Influence of diltiazem on cyclosporine clearance. Lancet 1986; i: 1387
207. Kohlhaw K, Wonigeit K, Frei U, et al. Effect of the calcium channel blocker diltiazem on cyclosporine A blood levels and dose requirements. Transplant Proc 1988; 20 Suppl. 2: 572-4
208. Copur MS, Tasdemir I, Turgan C, et al. Effects of nitrendipine on blood pressure and blood cyclosporine A level in patients with post transplant hypertension. Nephron 1989; 52: 227-30
209. Neumayer HH, Wagner K. Diltiazem and economic use of cyclosporin [letter]. Lancet 1986; ii: 523
210. Bourbigot B, Guiserix J, Airiau J, et al. Nicardipine increases cyclosporin blood levels [letter]. Lancet 1986; i: 1447
211. Maddux MS, Veremis SA, Bauma WD, et al. Significant drug interactions with cyclosporine. Hosp Ther 1987; 12: 55-70
212. Pochet JM, Pirson Y. Cyclosporin-diltiazem interaction [letter]. Lancet 1986; i: 979
213. Wagner J, Neumayer HH. Prevention of delayed graft function in cadaver kidney transplants by diltiazem [letter]. Lancet 1985; ii: 1355-6
214. Wagner K, Philipp T, Heinemeyer G, et al. Interaction of cyclosporin and calcium antagonists. Transplant Proc 1989; 21 (1): 1453-6
215. Kunzendorf U, Walz G, Brockmoeller J, et al. Effects of diltiazem upon metabolism and immunosuppressive action of cyclosporine in kidney graft recipients. Transplantation 1991; 52 (2): 280-4
216. Zeevi A, Venkataramanan R, Burckart G, et al. Sensitivity of activated human limphocytes to cyclosporine and its metabolites. Hum Immunol 1988; 21: 143-53
217. Freed BM, Rosano TG, Lempert N. In vitro immunosuppressive properties of cyclosporine matabolites. Transplantation 1986; 43: 123-7
218. Sketris IS, Methot ME, Nicol D, et al. Effect of calcium channel blockers on cyclosporine clearance and use in renal transplant patients. Ann Pharmacother 1994; 28: 1227-31
219. McCauley J, Ptachcinski RJ, Shapiro R. The cyclosporine-sparing effects of diltiazem in renal transplantation. Transplant Proc 1989; 21: 3955-7
220. Campistol JM, Oppenheimer F, Vilardell J, et al. Interaction between cyclosporin and diltiazem in renal transplant patienls. Nephron 1991; 57: 241-2
221. Chrysostomou A, Walker RG, Russ GR, et al. Diltiazem in renal allograft recipients receiving cyclosporine. Transplantation 1993; 55: 300-4
222. Tortorice KL, Heim-Duthoy KL, Awni WM, et al. The effects of calcium channel blockers on cyclosporine and its metabolites in renal transplant recipients. Ther Drug Monit 1990; 12: 321-8
223. Dy GR, Raja RM, Mendez MM. The clinical and biochemical effect of calcium channel blockers in organ transplant recipients on cyclosporine. Transplant Proc 1991; 23 (1) 1258-9
224. Webber IR, Peters WHM, Back DJ. Cyclosporin metabolism by human gastrointestinal mucosal microsomes. Br J Clin Pharmacol 1992; 33: 661-4
225. Sawchuk RJ, Awni WM. Absorption of cyclosporine from rabbit small intestine in situ. J Pharm Sci 1986; 75: 1151-6
226. Hamer AWF, Tanasescu DE, Marks JW, et al. Failure of episodic high-dose oral verapamil therapy to convert supraventricular tachycardia: a study of plasma verapamil levels and gastric motility. Am Heart J 1987; 114: 334-42
227. Shah I, Whiting PH, Omar G, et al. FK506 metabolism and drug interaction. Effects of FK506 on human hepatic microsomal cytochrome P450-dependent drug metabolism in vitro. Transplant Proc 1991; 23: 2783-5
228. Burke MD, Omar G, Thomson AW, et al. Inhibition of the metabolism of cyclosporine by human liver microsomes by FK506. Transplantation 1990; 50: 901-2
229. Christians U, Guengerich FP, Schimdt G, et al. In vitro metabolism of FK506, cytochrome P450 and drug interactions [abstract]. Ther Drug Monit 1993; 15: 145
230. Pichard L, Fabre I, Domergue J, et al. Effect of the FK506 on human hepatic cytochrome P-450: interaction with CyA. Transplant Proc 1991; 23: 2791-3
231. Omar G, Shah IA, Thomson AW, et al. FK506 inhibition of cyclosporine metabolism by human liver microsomes. Transplant Proc 1991; 23 (1) 934-5
232. Starzl TE, Todo S, Fung J, et al. FK506 for liver, kidney and pancreas transplantation. Lancet 1989; ii: 1000-4
233. Jain AB, Venkataramanan R, Fung J, et al. Pharmacokinetics of cyclosporine and nephrotoxicity in orthotopic liver transplant patients rescued with FK506 Transplant Proc 1991; 23: 2777-9
234. Zeevi A, Duquesnoy R, Eiras G, et al. Immunosuppressive effect of FK506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc 1987; 19 Suppl. 6: 404
235. McCauley J, Takaya S, Fung J, et al. The question of FK 506 nephrotoxicity after liver transplantation. Transplant Proc 1991d; 23(1): 1444-7
236. Ost L, Klintmalm G, Ringden O. Mutual interaction between prednisolone and cyclosporine in renal transplant patients. Transplant Proc 1985; 17: 1252-5
237. Klintmalm G, Sawe J. High dose methylprednisolone increases plasma cyclosporin levels in renal transplant recipients. Lancet 1984; i: 731
238. Ptachcinski RJ, Venkataramanan R, Burckart GJ, et al. Cyclosporine-high dose steroid interaction in renal transplant recipients: assessment by HPLC. Transplant Proc 1987; 19: 1728-9
239. Durrant S, Chipping PM, Palmer S, et al. Cyclosporine A, methylprednisolone and convulsions. Lancet 1982; i: 216-7
240. Hricik DE, Mortiz C, Mayes JT, et al. Association of the absence of steroid therapy with increased cyclosporine blood levels in renal transplant recipients. Transplant 1990; 49: 221-3
241. Brayman KL, Nakamura J, Naji A, et al. The effect of phénobarbital and methylprednisolone on the biotransformation of cyclosporine in the rat. Transplant Proc 1988; 20 Suppl. 2: 553-6
242. Ross WB, Roberts D, Griffin PJA, et al. Cyclosporin interaction with danazol and norethisterone. Lancet 1986; i: 330
243. Koneru B, Hartner C, Iwatsuki S, et al. Effects of danazol on cyclosporine pharmacokinetics. Transplantation 45: 1988; 1001
244. Leimenstoll G, Jessen P, Zabel P, et al. Arzneimittelschädigung der Laber bei Kombination von Cyclosporin A und einem Antikorzeplivum. Dtsch Med Wochenschr 1984; 109: 1989-90
245. Møller BB, Ekelund B. Toxicity of cyclosporine during treatment with androgens. New Engl J Med 1985; 313: 1416-7
246. Maurer G. Metabolism of cyclosporine. Transplant Proc 1985; 17 Suppl. 1: 19-26
247. Orme ML'E, Back DJ, Breckenridge AM. Clinical pharmacokinetics of oral contraceptive steroids. Clin Pharmacokinet 1983; 8: 95-136
248. Michaels RM, Rogers KD. A sex difference in immunologic responsiveness. Pediatrics 1971; 47: 120-3
249. Terasiki PI, Mickey MR, Cecka M, et al. Clinical kidney transplants, 1988. Immunol Lett 1988; 21: 33-8
250. Castro JE, Hamilton DNH. Adrenalectomy and orchidectomy as immunopotentiating procedures. Transplantation 1972; 13: 615-6
251. Hirasawa K, Enosawa S. Effects of sex steroids hormones on sex associated differences in the survival time of allogeneic skin graft in rats. Transplantation 1990; 50: 637-41
252. Hirasawa K, Kamada N. Female sex hormone, estradiol, antagonizes the immunosuppressive activity of cyclosporine in rat organ transplantation. Transplant Proc 1992; 24: 408-9
253. Cheng LP, Kuwahara M, Jacobsson J, et al. Inhibition of myointimal hyperplasia and macrophage infiltration by estradiol in aorta allografts. Transplantation 1991; 52: 967-72
254. Childester PD, Connito DJ. Interaction between glipizide and cyclosporine: report of two cases. Transplant Proc 1993; 25 (2): 2136-7
255. Prendergast BD. Glyburide and glipizide, second generation of sulfoniylurea hypoglycemic agents. Clin Pharm 1984; 3: 473-85
256. Brogden RN, Heel RC, Pakes GE, et al. Glipizide: a review of its pharmacological properties and therapeutic use. Drugs 1979; 18: 329-53
257. Yoshimura N, Nakai I, Ohmori Y, et al. Effect of cyclosporine on the endocrine and exocrine pancreas in kidney transplant recipients. Am J Kidney Dis 1988; 12: 11-7
258. Harris KP, Jenkins D, Walls J. Nonsteroidal antinflammatory drugs and cyclosporine: a potentially serious adverse interaction. Transplantation 1988; 46: 598-9
259. Dieterle A, Abeywickrarna K, Graffenried B. Nephrotoxicity and hypertension in patients with rheumatoid arthritis treated with cyclosporine. Transplant Proc 1988; 20 Suppl. 4: 349-55
260. Ludwin D, Bennett KJ, Grace EM, et al. Nephrotoxicity in patients with reumathoid arthritis treated with cyclosporine. Transplant Proc 1988; 20 Suppl. 4: 367-70
261. Berg KJ, Forre O, Bjerkhoel F, et al. Side effects of cyelosporin A treatment in patients with reumathoid arthritis. Kidney Int 1986; 29: 1180-7
262. Kovarik JM, Mueller EA, Gaber M, et al. Pharmacokinetics of cyclosporine and steady-state aspirin during coadministration. J Clin Pharmacol 1993; 33: 513-21
263. Dunn MJ. Nonsteroidal anti-inflammatory drugs and renal function. Annu Rev Med 1984; 35: 411-28
264. Billingham ME. Cardiac transplant atherosclerosis. Transplant Proc 1987; 19 Suppl. 5: 19-25
265. De Lorgeril M, Dureau G, Boissonnat P, et al. Platelet function and composition in heart transplant recipients compared with nontransplanted coronary patients. Arterioscler Thromb 1992; 12: 222-30
266. De Lorgeril M, Dureau G, Boissonnat P, et al. Increased platelet aggregation after heart transplantion: influence of aspirin. J Heart Lung Transplant 1991; 10: 600-3
267. Hass WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. New Engl J Med 1989; 321: 501-7
268. De Lorgeril M, Boissonnat P, Dureau G, et al. Evaluation of ticlopidine, a novel inhibitor of platelet aggregation, in heart transplant recipients. Transplantation 1993; 55: 1195-6
269. Birmele B, Lebranchu Y, Bagros P, et al. Interaction of cyclosporine and ticlopidine. Nephrol Dial Transplant 1991; 6 (2): 150-1
270. Smeesters C, Chaland P, Giroux L, et al. Prevention of acute cyclosporine A nephrotoxicity by a thromboxane synthetase inhibitor. Transplant Proc 1988; 20 (3 Suppl. 3): 658-64
271. 2 in kidney transplant patients. Transplant Proc 1988; 20 Suppl. 1: 424-7
272. Ahonen J, Isoniemi H, Eklund B, et al. Thromboxane-receptor antagonist in renal transplantation. Transplant Proc 1990; 22 (4): 1370
273. Violi F, Ghiselli A, Iuliano L, et al. Inhibition of picotamide of thromboxane production in vitro and ex vivo. Eur J Clin Pharmacol 1988; 33: 599-602
274. Gresele P, Deckmyn H, Arnoult J, et al. Characterization of N,N'-bis(3 picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A-2 receptor antagonist in human platelets. Thromb Haemost 1989; 61 (3): 479-84
275. Quarto Di Palo F, Elli A, Rivolta R, et al. Prevention of chronic cyclosporine nephrotoxicity in renal transplantation by picotamide. Transplant Proc 1991; 23 (1 Pt 2): 969-71
276. Moran M, Mozes MF, Maddux MS, et al. Prevention of acute graft rejection by the prostaglandin E-1 analogue misoprostol in renal-transplant recipients treated with cyclosporine and prednisone. New Engl J Med 1990; 322 (17): 1183-8
277. Bailey DG, Arnold JM, Spence JD. Grapefruit juice and drugs: how significant is this interaction?Clin Pharmacokinet 1994; 26: 91-8
278. Yee GC, Stanley DL, Pessa LJ, et al. Effect of grapefruit juice on blood cyclosporine concentration. Lancet 1995; 345: 955-6
279. Ducharme MP, Provenzano R, Dehoorne-Smith M, et al. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol 1993; 36: 457-9
280. Herlitz H, Edgar B, Hedner T, et al. Grapefruit juice: a possible source of variability in blood concentration of cyclosporine A. Nephrol Dial Transplant 1993; 8: 375
281. Bennett WM. Comparison of cyclosporine nephrotoxicity with aminoglycoside nephrotoxicity. Clin Nephrol 1986; 25 Suppl. 1: S126-9
282. Kahan BD. Cyclosporine. New Engl J Med 1989; 321: 1725-38
283. Holt DW, Marsden JT, Johnston A, et al. Blood cyclosporine concentrations and renal allograft dysfunction. BMJ 1986; 293: 1057-9
284. Termeer A, Hoitsma AJ, Koene RAP. Severe nephrotoxicity caused by the combined use of gentamicin and cyclosporine in renal allograft recipients. Transplantation 1986; 42: 220-1
285. Hows JM, Chipping PM, Fairhead S, et al. Nephrotoxicity in bone marrow transplant recipients treated with cyclosporine A. Br J Haematol 1983; 54: 69-78
286. Morales JM, Andres A, Prieto C, et al. Reversible acute renal toxicity by toxic sinergic effect between gentamicin and cyclosporine [letter]. Clin Nephrol 1988; 29: 272
287. Curtis JJ, Luke RG, Dubovsky E, et al. Cyclosporine in therapeutic doses increases renal allograft vascular resistance. Lancet 1986; ii: 477-9
288. Teraoka S, Takahashi K, Tanabe K, et al. Improvement in renal blood flow and kidney function by modulation of prostaglandin metabolism in cyclosporine-treated animals. Transplant Proc 1989; 21: 937-40
289. Elston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporin A. J Antimicrob Chemother 1988; 21: 679-89
290. Avent CK, Krinsky D, Kirklin JK, et al. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine. Am J Med 1988; 85: 452-3
291. Rosado LJ, Siskind MS, Copeland JG. Acute interstitial nephritis in a cardiac transplant recipient receiving ciprofloxacin. J Thorac Cardiovasc Surg 1994; 107: 1364-6
292. Hootkins R, Fenves AZ, Stephens MK. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature. Clin Nephrol 1989; 32: 75-8
293. Castelao AM, Sabate I, Grino JM, et al. Cyclosporine-drug interactions. Transplant Proc 1988; 20 Suppl. 6: 66-9
294. Nasir M, Rotellar C, Hand C, et al. Interaction between cyclosporin and ciprofloxacin. Nephron 1991; 57: 245-6
295. Edwards DJ, Bowles SK, Svensson CK, et al. Inhibition of drug metabolism by quinolone antibiotics. Clin Pharmacokinet 1988; 15: 194-204
296. Wolfson JS, Hooper DC. Comparative pharmacokinetics of ofloxacin and ciprofloxacin. Am J Med 1989; 87 (6C): 31S-36S
297. Van Buren DH, Koestner J, Adedoyin A, et al. Effect of ciprofloxacin on cyclosporine pharmacokinetics. Transplantation 1990; 50: 888-9
298. Lang J, De Villaine JF, Garraffo R, et al. Cyclosporine (cyclosporin A) pharmacokinetics in renal transplant patients receiving cyclosporine. Am J Med 1989; 87 Suppl. 5A: 82S-85S
299. Kruger HU, Schuler U, Proksch B, et al. Investigation of potential interaction of ciprofloxacin with cylosporine in bone marrow transplant recipients. Antimicrob Agents Chemother 1990; 34: 1048-52
300. Hooper TL, Gould FK, Swinburn CR, et al. Ciprofloxacin: a preferred treatment for legionella infections in patients receiving cyclosporine A [letter]. J Antimicrob Chemother 1988; 22: 952-3
301. Robinson JA, Venezio FR, Costanzo-Nordin MR, et al. Patients receiving quinolones and cyclosporine after heart transplantation. J Heart Transplant 1990; 9: 30-1
302. Tan KKC, Trull AK, Shawket S. Co-administration of ciprofloxacin and cyclosporin: lack of evidence for a pharmacokinetic interaction. Br J Clin Pharmacol 1989; 28: 185-7
303. Thomson DJ, Menkis AH, McKenzie FN. Norfloxacin-cyclosporine interaction. Transplantation 1988; 46: 312-3
304. Jadoul M, Pirson Y, Van Ypersele De Strihou C. Norfloxacin and cyclosporine, a safe combination [letter]. Transplantation 1989; 47: 747-8
305. Vogt P, Schorn T, Frei U. Ofloxacin in the treatment of urinary tract infection in renal transplant recipients. Infection 1988; 16: 175-8
306. Hoey LL, Lake KD. Does ciprofloxacin interact with cyclosporine? Ann Pharmacother 1994; 28 (1): 93-6
307. Ringden O, Myrenfors P, Klintmalm G, et al. Nephrotoxicity by co-trimoxazole and cyclosporine in transplanted patients [letter]. Lancet 1984; i: 1016-7
308. Fox BC, Sollinger HW, Belzer FO, et al. A prospective, randomized, double-blind study of trimethoprim-sulphametoxazole for prophylaxis of infection in renal transplantation: clinical efficacy, absorption of trimethoprim-sulphametoxazole, effects on the microflora and the cost-benefit of prophylaxis. Am J Med 1990; 89: 255-74
309. Albrechtsen D, Bendtal O, Berg KJ, et al. Infections in cyclosporine-treated kidney graft recipients: beneficial effect of cotrimoxazole prophylaxis. Transplant Proc 1990; 22: 245
310. Higgins RM, Bloom SL, Hopkin JM, et al. The risks and beneficts of low-dose cotrimoxazole prophylaxis for pneumocystis pneumonia in renal transplantation. Transplantation 1989; 47: 558-60
311. Berglund F, Killander J, Pompeius R. Effect of trimethoprimsulphametoxazole on the renal excretion of creatinine in man. J Urol 1975; 114: 802-8
312. Berg KJ, Nordby G, Rootwelt K, et al. Effects on renal function of combined treatment with trimethoprim and cyclosporine A in kidney transplant patients. Transplant Proc 1988; 20: 413-5
313. Coffman TM, Carr DR, Yarger WE, et al. Evidence that renal prostaglandin and thromboxane production is stimulated in chronic cyclosporine nephrotoxicity. Transplantation 1987; 43: 282-5
314. Chia JK, Pollack M. Amphotericin B induces tumor necrosis factor production by murine macrophages. J Infect Dis 1989; 159: 113-6
315. Kennedy MS, Deeg HJ, Siegel M, et al. Acute renal toxicity with combined use of ampholericin B and cyclosporine after marrow transplantation. Transplantation 1983; 35: 211-5
316. Tutschka PJ, Beschorner WE, Hess AD, et al. Cyclosporin-A to prevent graft-versus-host disease: a pilot study in 22 patients receiving allogeneic marrow transplants. Blood 1983; 61: 318-25
317. Branch RA. Prevention of amphotericin B-induced renal impairment. Arch Intern Med 1988; 148: 2389-94
318. Bianco JA, Almgren J, Kern DL, et al. Evidence that oral penlox fylline reverses acute renal dysfunction in bone marrow transplant recipients receiving amphotericin B and cyclosporine: results of a pilot study. Transplantation 1991; 51 (4): 925-7
319. 2) by pentoxifylline from human vascular tissue. Arzneimittel Forsch 1982; 32: 1315-8
320. Poggesi L, Boddi M, Scarti L, et al. Pentoxifylline and prostaglandins [in Italian]. Ric Clin Lab 1988; 18 Suppl. 2: 37-46
321. Strieter RM, Remick DG, Ward PA, et al. Cellular and molecular regulation of tumor necrosis factor-alpha production by pen oxifylline. Biochem Biophys Res Commun 1988; 155: 1231-6
322. Lopez-Berestein G, Bodey GP, Fainstein V, et al. Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 1989; 149: 2533-6
323. Tollenar J, Duraj F, Ericzon BG. Liposomal amphotericin B treatment in a 9-month old liver recipient. Mycoses 1990; 3: 251-2
324. Katz NM, Pierce PF, Anzeck RA, et al. Liposomal amphotericin B for treatment of pulmonary aspergillosis in a heart transplant patient. J Heart Transplant 1990; 9: 14-7
325. Bean B, Braun C, Balfour Jr HR. Acyclovir therapy for acute herpes zoster. Lancet 1982; ii: 118-21
326. Brigden D, Rosling AE, Woods NC. Renal function after acyclovir intravenous injection. Am J Med 1982; 73 (1A): 182-5
327. Shepp DH, Dandliker PS, Meyers JD. Treatment of varicellazoster virus infection in severely immunocompromised patients. A randomized comparison of acyclovir and vidaranine. New Engl J Med 1986; 314: 208-12
328. Stoffel M, Squifflet JP, Pirson Y, et al. Transplant Proc 1987; 19: 2190-3
329. Dorsky DI, Crumpacker CS. Drugs five years later: acyclovir. Ann Intern Med 1987; 107: 859-74
330. Balfour HH, Chace BA, Stapleton JT, et al. A randomized-placebo controlled trial or oral acyclovir for the prevention of cytomegulovirus disease in recipients of renal allografts. New Engl J Med 1989; 320: 1381-7
331. Hayes K, Shakuntala V, Pingle A, et al. Safe use of acyclovir (Zovirax) in renal transplant patients on cyclosporine A therapy: case reports. Transplant Proc 1992; 24: 1926
332. Johnson PC, Kumor K, Welsh MS, et al. Effect of coadministralion of cyclosporine and acyclovir on renal function of renal allograft recipients. Transplantation 1987; 44: 329-31
333. Rieger EH, Halasz NA, Wahlstrom HE. Colchicine neuromyopathy after renal transplantation. Transplantation 1990; 49: 1196-8
334. Menta R, Rossi E, Guariglia A, et al. Reversible acute cyclosporin nephrotoxicity induced by colchicine administration [letter]. Nephrol Dial Transplant 1987; 2: 380-1
335. Yussim A, Bar-Nathan N, Lustig S, et al. Gastrointestinal, hepatorenal and neuromuscular toxicity caused by cyclosporine-colchicine interaction in renal transplantation. Transplant Proc 1994; 26: 2825-6
336. Murray BM, Venuto RC, Kohli R, et al. Enalapril-associated acute renal failure in renal transplants: possible role of cyclosporine. Am J Kidney Dis 1990; 16: 66-9
337. Curtis JJ, Luke RG, Whelchel JD, et al. Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. New Engl J Med 1983; 308: 377-81
338. Hricik DE, Browning PJ, Kopelman R, et al. Captopril-induced functional renal insufficiency in patients with bilateral renal artery stenosys in a solitary kidney. New Engl J Med 1983; 308: 373-6
339. van der Woude FJ, van Son WJ, Tegzess AM, et al. Effect of captopril on blood pressure and renal function in patients with transplant renal artery stenosis. Nephron 1985; 39: 184-8
340. Lumley HS, Powels R, Morgenstern GR, et al. Pseudosyngeneic transplantation as a treatment for recurrent leukaemia following allogeneic bone marrow transplantation. In: Touraine J. Gluckman E, Griscelli C, editors. Bone marrow transplantation in Europe, II. Amsterdam: Excerpta Medica, 1981: 24-8
341. Leahey Jr EB, Reiffel JA, Drusin RE, et al. Interaction between quinidine and digoxin. JAMA 1978; 240: 533-6
342. Moysey JO, Jaggarao NSU, Grundy EN, et al. Amiodarone increases plasma digoxin concentration. BMJ 1981; 282: 272
343. Pedersen KE, Dorph-Pedersen A, Hvidt S, et al. Digoxin-verapamil interaction. Clin Pharmacol Ther 1981; 30: 311-6
344. Zalzstein E, Bryson SM, Koren G. Interaction between digoxin propafenazone in children. J Pediatrics 1990; 116: 310-2
345. Dorian P, Strauss M, Cardella C, et al. Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporine treatment. Clin Invest Med 1988; 11: 108-12
346. Dorian P, Strauss MH, Cardella C, et al. Digoxin-cyclosporine interaction: severe digitalis toxicity after cyclosporin treatment. Clin Invest Med 1988; 11: 108-112
347. Robieux I, Dorian P, Klein J, et al. The effects of cardiac transplantation and cyclosporine therapy on digoxin pharmacokinetics. J Clin Pharmacol 1992; 32: 338-43
348. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25: 2732-4
349. Regazzi MB, Iacona I, Campana C, et al. Clinical efficacy and pharmacokinetics of HMG-CoA reductase inhibitors in heart transplant patients treated with cyclosporin A. Transplant Proc 1994; 26: 2644-5
350. Campana C, Iacona I, Regazzi MB, et al. Efficacy and pharmacokinetics of simvastatin in heart transplant recipients. Annals of Pharmacother 1995; 29: 235-9
351. Smith PF, Eydelloth RS, Grossman SJ, et al. HMG-CoA reductase inhibitors-induced miopathy in the rat: cyclosporine A interaction and mechanism studies. J Pharmacol Exp Ther 1991; 257: 1225-35
352. Norman DJ, IIlingworth DR, Munson J, et al. Myolisis and acute renal failure in a heart transplant recipient receiving lovaslatin [letter]. New Engl J Med 1988; 318: 46-7
353. Arellano F, Krupp P. Muscular disorders associated with cyclosporin [letter]. Lancet 1991; 337: 915
354. Barhir M, Rose M, Kushwaha S, et al. Low dose simvastatin for the treatment of hypercholesterolaemia in recipients of cardiac transplantation. Int J Cardiol 1991; 33: 241-6
355. Vanhaecke J, Van Cleemput J, Van Lierde J, et al. Safety and efficacy of low dose simvastatin in cardiac transplant recipients treated with cyclosporine. Transplantation 1994; 58: 42-5
356. Ballantyne CM, Podet EJ, Patsch WP, et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 53-6
357. De Groen PC. Cyclosporine, low-density lipoprotein, and cholesterol. Mayo Clin Proc 1988; 63: 1012-21
358. List A, Spier C, Greer J, et al. Biochemical modulation of anthracycline resistance in acute leukemia with cyclosporin A. Proc Am Soc Clin Oncol 1992; 11: 264
359. Rushing DA, Raber SR, Rodvold KA, et al. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer. Cancer 1994; 74: 834-41
360. Erlichman C, Moore M, Thiessen JJ, et al. Phase I pharmacokinetic studies of cyclosporin A combined with doxorubicin. Cancer Res 1993; 53: 4837-42
361. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992; 10: 1635-42
362. Lum BL, Fisher GA, Brophy NA, et al. Clinical trials of modulation of multidrug resistance. Pharmacokinetic and pharmacodynamic consideration. Cancer 1993; 72 Suppl. 11: 3502-14
363. Marie J-P, Bastrie JN, Coloma F, et al. A phase I-II trial of cyclosporine with etoposide and miloxantrone in advanced acute leukemia. Proc Am Soc Clin Oncol 1992; 11: 275
364. Samuels B, Ratain M, Mick R, et al. Phase I trial of multidrug resistance modulation with cyclosporin A. Proc Am Assoc Cancer Res 1991; 32: 195
365. Lum BL, Gosland MP, Kaubisch S, et al. Molecular targets in oncology: implications of the multidrug resistance gene. Prrarmacotherapy 1993; 13 (2): 88-109
366. Pastan I, Gottesman MM. Multidrug resistance. Annu Rev Med 1991; 42: 277-86
367. Speth PAJ, van Hoesel QG, Haanen C. Clinical pharmacokinetics of doxorubicin. Clin Pharmacokinet 1988; 15: 15-31